Conference
CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570)
Authors
Kassouf W; Crabb SJ; Duran I; Brundage MD; Reaume MN; Dragomir A; Wyatt AW; Badillo FEV; Lukka H; Niazi T
Volume
40
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
June 1, 2022
Name of conference
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
ELECTR NETWORK
Conference start date
June 3, 2022
Conference end date
June 7, 2022
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
16
ISSN
0732-183X